Exelixis Submits Cabo NDA in Medullary Thyroid Cancer

Just in time for the American Society of Clinical Oncology (ASCO) meeting in Chicago, Exelixis Inc. completed the filing of its rolling new drug application (NDA) with the FDA for cabozantinib (XL184) in the lead indication of progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).